Immune aging follows different paths. In healthy people it is gradual, while in chronic diseases such as type 2 diabetes it can speed up. This work sits amid studies of how T cells recognize the enemy, how sentinel cells build a trap for cancer, and why hunter cells get tired. This paper adds an important stroke to that picture: it shows that the inflammatory environment in diabetes does not simply accelerate aging, it changes the very trajectory of T cell development.
The researchers took blood from older adults with and without type 2 diabetes, as well as from patients with cardiomyopathy. Using flow cytometry, they divided CD8+ T cells into subtypes by the markers CD45RA, CCR7, CD27, and CD28. They then measured telomere length, analyzed the diversity of T cell receptors, and tested how the cells respond to stimulation. To understand the role of TGFβ1, they incubated cells from healthy donors with this molecule and looked for signs typical of diabetes. In addition, they labeled cells with radioactive zirconium-89 and injected them into mice to track their movement through the body.
Patients with diabetes had more highly differentiated memory T cells (TEMRA), which had shorter telomeres and a less diverse set of receptors. At the same time, these cells carried fewer KLRG1, NKG2D, and NKG2A receptors, which normally help T cells kill infected or senescent cells. Instead, the KLRG1 receptor accumulated inside the cell, pointing to a failure in its return to the surface. Blood levels of TGFβ1 were higher in people with diabetes, and treating healthy cells with TGFβ1 reproduced these changes: it lowered KLRG1, NKG2D, and NKG2A, raised p21, and reduced rab11a. Moreover, T cells from people with diabetes released cytotoxic granules less efficiently after stimulation, even though they had no fewer granules. In mouse experiments, cells from people with diabetes accumulated in the spleen more strongly than cells from healthy people.
This work stands out from its neighbors because it links immune aging not simply to age but to a specific disease. It shows that the inflammatory environment in diabetes does not merely accelerate aging: it creates a special type of T cell that loses the ability to carry out normal immune surveillance. This may explain why people with diabetes face a higher risk of infections and cancers. The work also points to TGFβ1 as a possible therapeutic target, but stresses that simply removing inflammation may not be enough.
The next step is to find out whether these changes are reversible. If TGFβ1 or inflammation is removed, will the cells return to a normal state? It is also necessary to test how much these T cells really do a worse job of protecting against infections and cancer in a living organism. Methods may emerge that help restore receptors on the cell surface or improve their cytotoxicity.
The results matter for understanding immunodeficiency in diabetes and may influence the development of therapies aimed at restoring T cell function. They are also useful for gerontology, since they show how chronic diseases distort the normal aging of the immune system.
Test how removing TGFβ1 or blocking its signaling pathway affects the phenotype and function of TEMRA cells in patients with diabetes. Assess whether pharmacological agents can restore NK receptor expression and cytotoxicity.
Immunology still has an open question: why does immune surveillance weaken in chronic inflammatory diseases? This work links the loss of NK receptors and impaired degranulation to a specific TGFβ1 signaling pathway, which offers a new point of attack for future research. However, it remains unclear whether this is a common feature of all chronic inflammation or specific to diabetes.
In patients with diabetes, memory T cells have shorter telomeres but more telomerase (TERT) than those of healthy peers. This looks paradoxical: the cell tries to compensate for wear and tear but cannot stop aging.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.